Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease specialist Alumis as part of an all-stock merger.
SAN FRANCISCO — For any hopes the dealmaking ... A biotech stock index slid by almost 3%. Amgen is one of those would-be competitors and, at the JPM meeting, executives defended recent trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback